|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
NZ227684A
(en)
|
1988-01-30 |
1991-07-26 |
Merck Sharp & Dohme |
Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
|
|
GB9005737D0
(en)
|
1990-03-14 |
1990-05-09 |
Beecham Group Plc |
Novel compounds
|
|
FR2676444B1
(fr)
|
1991-05-16 |
1995-03-10 |
Sanofi Elf |
Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
EP1440311B1
(en)
|
2001-08-31 |
2009-01-07 |
Gen-Probe Incorporated |
Affinity-shifted probes for quantifying analyte polynucleotides
|
|
US6992087B2
(en)
|
2001-11-21 |
2006-01-31 |
Pfizer Inc |
Substituted aryl 1,4-pyrazine derivatives
|
|
US7135484B2
(en)
|
2002-08-14 |
2006-11-14 |
Abbott Laboratories |
Azabicyclic compounds are central nervous system active agents
|
|
EP1785425B1
(en)
|
2002-09-30 |
2009-03-25 |
NeuroSearch A/S |
1,4-Diazabicycloalkane derivatives, their preparation and use
|
|
DE602004023586D1
(de)
|
2003-02-27 |
2009-11-26 |
Neurosearch As |
Neue diazabicyclische arylderivate
|
|
US8014953B2
(en)
|
2003-08-08 |
2011-09-06 |
The Regents Of The University Of California |
RNA surveillance among curated proteins
|
|
US7399765B2
(en)
|
2003-09-19 |
2008-07-15 |
Abbott Laboratories |
Substituted diazabicycloalkane derivatives
|
|
US7309699B2
(en)
|
2003-12-22 |
2007-12-18 |
Abbott Laboratories |
3-Quinuclidinyl amino-substituted biaryl derivatives
|
|
US7655657B2
(en)
|
2003-12-22 |
2010-02-02 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7160876B2
(en)
|
2003-12-22 |
2007-01-09 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7309487B2
(en)
|
2004-02-09 |
2007-12-18 |
George Inana |
Methods and compositions for detecting and treating retinal diseases
|
|
AR049401A1
(es)
|
2004-06-18 |
2006-07-26 |
Novartis Ag |
Aza-biciclononanos
|
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
|
CA2583572C
(en)
|
2004-10-07 |
2016-07-12 |
Merck & Co., Inc. |
Thiazolyl mglur5 antagonists and methods for their use
|
|
EP1809282B1
(en)
|
2004-10-18 |
2013-01-09 |
Amgen, Inc |
Thiadiazole compounds and methods of use
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
ATE451363T1
(de)
|
2005-01-26 |
2009-12-15 |
Schering Corp |
3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
|
|
TW200716594A
(en)
|
2005-04-18 |
2007-05-01 |
Neurogen Corp |
Substituted heteroaryl CB1 antagonists
|
|
US7598052B2
(en)
|
2005-10-11 |
2009-10-06 |
The Regents Of The University Of Michigan |
Expression profile of thyroid cancer
|
|
US8603457B2
(en)
|
2005-12-02 |
2013-12-10 |
University Of Rochester |
Nonsense suppression and genetic codon alteration by targeted modification
|
|
US7834178B2
(en)
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
|
PL2018380T3
(pl)
|
2006-05-19 |
2012-05-31 |
Abbvie Bahamas Ltd |
Skondensowane azabicykliczne pochodne alkanowe podstawione bicykloheterocyklem o aktywności wobec OUN
|
|
WO2007138038A1
(en)
|
2006-05-30 |
2007-12-06 |
Neurosearch A/S |
Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
|
|
US8314119B2
(en)
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
US8343941B2
(en)
|
2007-03-30 |
2013-01-01 |
Rutgers, The State University Of New Jersey |
Compositions and methods for gene silencing
|
|
US8283116B1
(en)
|
2007-06-22 |
2012-10-09 |
Ptc Therapeutics, Inc. |
Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
ES2639852T3
(es)
|
2007-10-26 |
2017-10-30 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarrestar los trastornos musculares
|
|
WO2009067579A1
(en)
|
2007-11-21 |
2009-05-28 |
Abbott Laboratories |
Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
|
|
JP5177219B2
(ja)
|
2008-03-18 |
2013-04-03 |
コニカミノルタホールディングス株式会社 |
電気化学的表示素子
|
|
US8309577B2
(en)
|
2008-04-23 |
2012-11-13 |
Bristol-Myers Squibb Company |
Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
|
|
WO2009151546A2
(en)
|
2008-05-27 |
2009-12-17 |
Ptc Therapeutics, Inc. |
Methods for treating spinal muscular atrophy
|
|
US8133724B2
(en)
|
2008-09-17 |
2012-03-13 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
|
|
SG172352A1
(en)
|
2008-12-23 |
2011-07-28 |
Abbott Lab |
Anti-viral compounds
|
|
CN102482677B
(zh)
|
2009-03-16 |
2017-10-17 |
库尔纳公司 |
通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
|
|
CA2758189C
(en)
|
2009-04-10 |
2020-12-29 |
Association Institut De Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
|
ES2699827T3
(es)
|
2009-06-17 |
2019-02-13 |
Biogen Ma Inc |
Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
|
|
JO3250B1
(ar)
|
2009-09-22 |
2018-09-16 |
Novartis Ag |
إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
|
|
EP2305679A1
(en)
|
2009-09-28 |
2011-04-06 |
GenKyoTex SA |
Pyrazoline dione derivatives as nadph oxidase inhibitors
|
|
EP2525797A1
(en)
|
2010-01-20 |
2012-11-28 |
Abbott Laboratories |
Methods for treating pain
|
|
ES2579949T3
(es)
|
2010-02-05 |
2016-08-17 |
Heptares Therapeutics Limited |
Derivados de 1,2,4-triazin-4-amina
|
|
US9133123B2
(en)
|
2010-04-23 |
2015-09-15 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
JP6069661B2
(ja)
|
2010-06-24 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
|
|
PE20130774A1
(es)
|
2010-07-29 |
2013-06-26 |
Rigel Pharmaceuticals Inc |
Compuestos heterociclicos activadores de ampk y metodos para emplearlos
|
|
SG193370A1
(en)
|
2011-03-14 |
2013-10-30 |
Nse Products Inc |
Oral formulations for promoting cellular purification
|
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
US9447075B2
(en)
|
2011-08-02 |
2016-09-20 |
The Brigham And Women's Hospital, Inc. |
Pyridazine derivatives as EAAT2 activators
|
|
EP2771069A4
(en)
|
2011-10-27 |
2015-08-26 |
Mayo Foundation |
INHIBITION OF G-PROTEIN-COUPLED RECEPTOR-6-KINASE POLYPEPTIDE
|
|
KR102057351B1
(ko)
|
2011-12-30 |
2019-12-18 |
피티씨 테라퓨틱스, 인크. |
척수성 근위축증을 치료하기 위한 화합물
|
|
PL2809322T3
(pl)
|
2012-01-26 |
2019-11-29 |
Ptc Therapeutics Inc |
Związki do leczenia zaniku mięśni pochodzenia rdzeniowego
|
|
DK2812004T3
(en)
|
2012-02-10 |
2018-10-15 |
Ptc Therapeutics Inc |
COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
|
|
WO2013117693A1
(en)
|
2012-02-10 |
2013-08-15 |
Glaxosmithkline Intellectual Property Development Limited |
Pde4 inhibitor for treating huntington's disease
|
|
CN104302181B
(zh)
|
2012-03-01 |
2017-09-15 |
Ptc医疗公司 |
用于治疗脊髓性肌萎缩的化合物
|
|
KR102109992B1
(ko)
|
2012-03-23 |
2020-05-13 |
피티씨 테라퓨틱스, 인크. |
척수성 근위축증을 치료하기 위한 화합물
|
|
US8729263B2
(en)
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
|
ES2762326T5
(es)
|
2012-10-15 |
2023-04-27 |
Ionis Pharmaceuticals Inc |
Métodos para modular la expresión de C9ORF72
|
|
KR101879919B1
(ko)
|
2013-01-15 |
2018-07-18 |
노파르티스 아게 |
알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
|
|
JP6338223B2
(ja)
|
2013-01-15 |
2018-06-06 |
ノバルティス アーゲー |
アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
|
|
MX362819B
(es)
|
2013-01-15 |
2019-02-18 |
Novartis Ag |
Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.
|
|
US9040712B2
(en)
|
2013-01-23 |
2015-05-26 |
Novartis Ag |
Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
|
|
WO2014209841A2
(en)
|
2013-06-25 |
2014-12-31 |
F. Hoffmann-La Roche Ag |
Compounds for treating spinal muscular atrophy
|
|
KR20210130843A
(ko)
|
2013-07-31 |
2021-11-01 |
노파르티스 아게 |
1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도
|
|
WO2015024876A2
(en)
|
2013-08-19 |
2015-02-26 |
F. Hoffmann-La Roche Ag |
Screening method
|
|
US20230009804A1
(en)
|
2013-08-23 |
2023-01-12 |
Ateb, Inc. |
Machine-learning techniques for generating entity instructions
|
|
CN105612152A
(zh)
|
2013-08-26 |
2016-05-25 |
普渡制药公司 |
氮杂螺[4.5]癸烷衍生物及其用途
|
|
EP3052654A4
(en)
|
2013-09-30 |
2017-05-03 |
The Regents of the University of California |
Identification of structurally similar small molecules that enhance therapeutic exon skipping
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
TWI674257B
(zh)
|
2014-03-14 |
2019-10-11 |
日商拉夸里亞創藥股份有限公司 |
作為ｔｒｐｍ８拮抗劑之氮雜螺衍生物
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
EP3155128B1
(en)
|
2014-06-10 |
2019-05-15 |
Erasmus University Medical Center Rotterdam |
Methods for characterizing alternatively or aberrantly spliced mrna isoforms
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
WO2016027168A2
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
|
US20170355956A1
(en)
|
2014-09-04 |
2017-12-14 |
Rutgers, The State University Of New Jersey |
Compositions for increasing survival of motor neuron protein (smn) levels in target cells and methods of use thereof for the treatment of spinal muscular atrophy
|
|
WO2016064895A1
(en)
|
2014-10-20 |
2016-04-28 |
The Brigham And Women's Hospital, Inc. |
Targeting apolipoprotein e (apoe) in neurologic disease
|
|
US10053697B1
(en)
|
2015-01-09 |
2018-08-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Programmable alternative splicing devices and uses thereof
|
|
NZ734082A
(en)
|
2015-01-20 |
2019-01-25 |
Boehringer Ingelheim Animal Health Usa Inc |
Anthelmintic compounds, compositions and method of using thereof
|
|
WO2016128343A1
(en)
*
|
2015-02-09 |
2016-08-18 |
F. Hoffmann-La Roche Ag |
Compounds for the treatment of cancer
|
|
EP3053577A1
(en)
|
2015-02-09 |
2016-08-10 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
|
EP4249472A3
(en)
|
2015-05-30 |
2023-12-13 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
CA3217238A1
(en)
|
2015-07-20 |
2017-01-26 |
Genzyme Corporation |
Colony stimulating factor-1 receptor (csf-1r) inhibitors
|
|
US20180271803A1
(en)
|
2015-09-02 |
2018-09-27 |
Pathways Bioscience, Llc |
Compositions and methods for treatment or prevention of oral mucositis
|
|
WO2017051353A1
(en)
|
2015-09-24 |
2017-03-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Modulators of indoleamine 2,3-dioxygenase
|
|
WO2017062751A1
(en)
|
2015-10-08 |
2017-04-13 |
The Regents Of The University Of California |
Compounds and methods for promoting stress resistance
|
|
CN108603230A
(zh)
|
2015-10-09 |
2018-09-28 |
南安普敦大学 |
基因表达的调节与蛋白质表达失调的筛选
|
|
JP6659841B2
(ja)
|
2015-11-12 |
2020-03-04 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
脊髄性筋萎縮症を処置するための組成物
|
|
US20180344680A1
(en)
|
2015-12-08 |
2018-12-06 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
|
|
IL294124B2
(en)
|
2015-12-10 |
2024-02-01 |
Ptc Therapeutics Inc |
Methods for treating huntington's disease
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
US11135221B2
(en)
|
2015-12-23 |
2021-10-05 |
Moonshot Pharma Llc |
Methods for inducing an immune response
|
|
CN109071524A
(zh)
|
2016-01-15 |
2018-12-21 |
布里格姆及妇女医院股份有限公司 |
作为eaat2活化剂的哒嗪衍生物
|
|
CA3012700A1
(en)
|
2016-02-01 |
2017-08-10 |
Arrakis Therapeutics, Inc. |
Compounds and methods of treating rna-mediated diseases
|
|
AU2017223706A1
(en)
|
2016-02-23 |
2018-09-20 |
Indiana University Research & Technology Corporation |
Combination therapies for treatment of spinal muscular atrophy
|
|
US11674952B2
(en)
|
2016-02-24 |
2023-06-13 |
The Rockefeller University |
Embryonic cell-based therapeutic candidate screening systems, models for Huntington's Disease and uses thereof
|
|
WO2017147509A1
(en)
|
2016-02-25 |
2017-08-31 |
Marco Colonna |
Compositions comprising trem2 and methods of use thereof
|
|
US20170268066A1
(en)
|
2016-03-15 |
2017-09-21 |
Chalmers Ventures Ab |
Cancer biomarkers
|
|
US11026936B2
(en)
|
2016-03-29 |
2021-06-08 |
Merck Patent Gmbh |
Piperidinyl-propanone derivatives
|
|
US10940161B2
(en)
|
2016-04-04 |
2021-03-09 |
University Of Florida Research Foundation, Incorporated |
Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
|
|
EP3442960A1
(en)
|
2016-04-12 |
2019-02-20 |
Esteve Pharmaceuticals, S.A. |
Arylamide derivatives having multimodal activity against pain
|
|
NZ789269A
(en)
|
2016-06-13 |
2026-01-30 |
Scholar Rock Inc |
Use of myostatin inhibitors and combination therapies
|
|
JP2019523242A
(ja)
|
2016-07-01 |
2019-08-22 |
アラーキス セラピューティクス， インコーポレイテッド |
Ｒｎａ機能をモジュレートするための化合物および方法
|
|
EA201991309A1
(ru)
|
2016-11-28 |
2019-11-29 |
|
Способы модуляции сплайсинга рнк
|
|
WO2018151326A1
(ja)
|
2017-02-20 |
2018-08-23 |
国立大学法人京都大学 |
スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
|
|
EP3628055A4
(en)
|
2017-05-01 |
2021-06-09 |
Thomas Jefferson University |
Systems-level analysis of tcga cancers reveals disease trna fragmentation patterns and associations with messenger rnas and repeat
|
|
KR20200017476A
(ko)
|
2017-06-14 |
2020-02-18 |
피티씨 테라퓨틱스, 인크. |
Rna 스플라이싱의 변경 방법
|
|
WO2019005993A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
METHODS OF TREATING HUNTINGTON'S DISEASE
|
|
US11382918B2
(en)
|
2017-06-28 |
2022-07-12 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's Disease
|
|
WO2019028440A1
(en)
|
2017-08-04 |
2019-02-07 |
Skyhawk Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING SPLICING
|
|
US11266640B2
(en)
|
2017-09-20 |
2022-03-08 |
Hangzhou Innogate Pharma Co., Ltd. |
Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
|
|
TW201930292A
(zh)
|
2017-10-12 |
2019-08-01 |
美商銳新醫藥公司 |
作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
|
|
WO2019084140A1
(en)
|
2017-10-24 |
2019-05-02 |
Sangamo Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES
|
|
EP3479845A1
(en)
|
2017-11-06 |
2019-05-08 |
Stalicla S.A. |
Challenge test for diagnosing subtype of autism spectrum disease
|
|
US10905707B2
(en)
|
2017-11-10 |
2021-02-02 |
University Of Massachusetts |
Compositions and methods for the treatment of expanded repeat-associated disorders
|
|
MX2020009957A
(es)
|
2018-03-27 |
2021-01-15 |
Ptc Therapeutics Inc |
Compuestos para el tratamiento de enfermedad de hungtinton.
|
|
CN112272666A
(zh)
|
2018-04-10 |
2021-01-26 |
斯基霍克疗法公司 |
用于治疗癌症的化合物
|
|
PL3814357T3
(pl)
|
2018-06-27 |
2024-09-16 |
Ptc Therapeutics, Inc. |
Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
|
|
EP3814360B8
(en)
|
2018-06-27 |
2024-11-06 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
BR112020026637A2
(pt)
|
2018-06-27 |
2021-03-30 |
Reborna Biosciences, Inc. |
Agente profilático ou terapêutico para atrofia muscular espinhal
|
|
EP3814345B8
(en)
|
2018-06-27 |
2024-10-30 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
US11987568B2
(en)
|
2018-08-03 |
2024-05-21 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Allosteric inhibitor of WEE1 kinase
|
|
TW202028183A
(zh)
|
2018-10-10 |
2020-08-01 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
|
CN113692402A
(zh)
|
2019-02-04 |
2021-11-23 |
斯基霍克疗法公司 |
用于调节剪接的方法和组合物
|
|
WO2020163382A1
(en)
|
2019-02-04 |
2020-08-13 |
Skyhawk Therapeutics, Inc. |
Methods and compositions for modulating splicing
|
|
WO2020163248A1
(en)
|
2019-02-04 |
2020-08-13 |
Skyhawk Therapeutics, Inc. |
Methods and compositions for modulating splicing
|
|
JP2022519294A
(ja)
|
2019-02-04 |
2022-03-22 |
スカイホーク・セラピューティクス・インコーポレーテッド |
スプライシングを調節するための方法および組成物
|
|
CN113677342A
(zh)
|
2019-02-05 |
2021-11-19 |
斯基霍克疗法公司 |
用于调节剪接的方法和组合物
|
|
CN114126613A
(zh)
|
2019-02-05 |
2022-03-01 |
斯基霍克疗法公司 |
用于调节剪接的方法和组合物
|
|
EP3920915A4
(en)
|
2019-02-05 |
2022-10-05 |
Skyhawk Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING SPLICE
|
|
KR20210134657A
(ko)
|
2019-02-05 |
2021-11-10 |
스카이호크 테라퓨틱스, 인코포레이티드 |
스플라이싱을 조절하는 방법 및 조성물
|
|
EP3920918A4
(en)
|
2019-02-05 |
2022-11-16 |
Skyhawk Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
|
|
US20230008867A1
(en)
|
2019-02-05 |
2023-01-12 |
Skyhawk Therapeutics, Inc. |
Methods and compositions for modulating splicing
|
|
WO2020163544A1
(en)
|
2019-02-06 |
2020-08-13 |
Skyhawk Therapeutics, Inc. |
Methods and compositions for modulating splicing
|
|
CN113661162A
(zh)
|
2019-02-06 |
2021-11-16 |
斯基霍克疗法公司 |
用于调节剪接的方法和组合物
|
|
JP2022525417A
(ja)
|
2019-03-15 |
2022-05-13 |
スカイホーク・セラピューティクス・インコーポレーテッド |
異常スプライシングを修正するための組成物および方法
|
|
US11129829B2
(en)
|
2019-06-17 |
2021-09-28 |
Skyhawk Therapeutics, Inc. |
Methods for modulating splicing
|
|
WO2021071984A1
(en)
|
2019-10-08 |
2021-04-15 |
Skyhawk Therapeutics, Inc. |
Compounds for modulating splicing
|
|
WO2021071981A1
(en)
|
2019-10-08 |
2021-04-15 |
Skyhawk Therapeutics, Inc. |
Compounds for modulating splicing
|
|
MX2022010634A
(es)
|
2020-02-28 |
2023-01-19 |
Remix Therapeutics Inc |
Derivados de piridazina para modular el empalme de acidos nucleicos.
|
|
JP7736700B2
(ja)
|
2020-02-28 |
2025-09-09 |
リミックス セラピューティクス インコーポレイテッド |
複素環アミド及びスプライシングを調節するためのその使用
|
|
WO2021174167A1
(en)
|
2020-02-28 |
2021-09-02 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|
|
CA3169697A1
(en)
|
2020-02-28 |
2021-09-02 |
Dominic Reynolds |
Thiophenyl derivatives useful for modulating nucleic acid splicing
|
|
JP2023520916A
(ja)
|
2020-04-08 |
2023-05-22 |
リミックス セラピューティクス インコーポレイテッド |
スプライシングを調整するための化合物及び方法
|
|
KR20230005210A
(ko)
|
2020-04-08 |
2023-01-09 |
레믹스 테라퓨틱스 인크. |
스플라이싱을 조절하기 위한 화합물 및 방법
|
|
EP4192454B1
(en)
|
2020-08-05 |
2026-04-22 |
Skyhawk Therapeutics, Inc. |
Azabicyclo-amino-triazine compounds for modulating splicing for the treatment of neurological diseases
|
|
WO2022031998A2
(en)
|
2020-08-05 |
2022-02-10 |
Skyhawk Therapeutics, Inc. |
Process for the preparation of intermediates useful in the preparation of compounds that modulate splicing
|
|
WO2022060951A1
(en)
|
2020-09-16 |
2022-03-24 |
Skyhawk Therapeutics, Inc. |
Compositions for modulating splicing
|
|
US20240368163A1
(en)
|
2021-08-30 |
2024-11-07 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|